65,437 trials
Psoriasis
Primary: Flow Mediated Dilation (FMD) at Week 12 Followed by Secukinumab 300 mg vs Pooled Placebo Treatment — 5.23; 3.65 Percentage maximal increase in diameter — p=0.2230
Rheumatoid Arthritis
Primary: Time to First Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated Event — NA; NA Months
Healthy Volunteers
Primary: Glycemic Index — 100; 33.68; 12.83 % of GI of the glucose
Hepatocellular Carcinoma
Primary: Blood Volume (BV) According to Degree of Lesions Differentiation — 15.930; 13.958 mL/100 grams
Pulmonary Disease, Chronic Obstructive
Primary: Part A: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event — 2; 9; 0; 1 Participants
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Progression-free Survival (PFS) — 4.83; 7.23 months
Tooth Replacement
Primary: Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. — 7.6758; 9.2208; 4.6085; 5.2331 Average Delta ∆ (Ct)
Chronic Liver Disease
Primary: Agreement in Measured Liver Stiffness Between ARFI and MRE — 3.21; 2.48; 1.81; 2.0 kPa
Chronic Idiopathic Urticaria
Primary: The Change in Diary-based Clinical Symptoms as Measured by the Urticaria Activity Score 7 (UAS7) — 20.46; 24.59; 18.83; 18 UAS7 Scores
Caffeine · Affect · Cognitive Ability, General
Primary: Mood State Score on POMS-2 Test — 2.63; 14.08; 2.19; 2.54 units on a scale
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Overall Survival — 5.9 months
HCV HIV
Primary: Number of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 516 Participants
Food Allergy · Peanut Allergy
Primary: Number of Participants Who Experienced a Decrease in Pn-BHR Area Under the Curve (AUC) of > 80% Compared With Baseline Values Before Week 8 — 5; 9 Participants
Stroke
Primary: Fugl-Meyer Assessment of Upper Extremity (FMA) — 22.50 units on a scale — p=<.05
Marijuana Smoking
Primary: Measure of Relapse: Change in Puffs Chosen Between Baseline and Relapse Phase — 2.5; 1.5 Puffs